OSI-774/Cisplatin/Taxotere in Head & Neck Squamous Cell Cancer
Status:
Active, not recruiting
Trial end date:
2021-09-01
Target enrollment:
Participant gender:
Summary
The goal of this clinical research study is to learn if giving the new drug, Tarceva®
(OSI-774), in combination with Platinol® (cisplatin) and Taxotere® (docetaxel) is effective
in the treatment of metastatic or recurrent head and neck cancer. The safety of this
treatment will also be studied.